the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Pediatric Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- patients's response to the LMA insertion
Study Overview
Brief Summary
This research attempts to find the optimum dose of remifentanil that can prevent the unnecessary responses such as coughing, gagging, and movement when LMA is inserted during sevoflurane induction in pediatric patients.
Detailed Description
Anaesthesia is induced by inhalation with 3% sevoflurane. A predetermined bolus dose of remifentanil is injected over 30 seconds. The LMA is attempted 60 seconds after bolus administration. The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- Single (Investigator)
Eligibility Criteria
- Ages
- 3 Years to 12 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •American Society of Anesthesiologists physical status 1 or 2
- •undergoing short elective surgery(i.e Strabismus surgery, Entropion surgery, Inguinal hernia surgery, etc) under general anesthesia
Exclusion Criteria
- •suspected difficult airways
- •respiratory disease (chronic obstructive pulmonary disease, upper respiratory infection)
- •body mass index > 30 kg/m2
- •allergies to the study drugs
- •a history of gastric reflux
Arms & Interventions
group R
The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
Intervention: Remifentanil (Drug)
Outcomes
Primary Outcomes
patients's response to the LMA insertion
Time Frame: 2 minutes after LMA insertion
Fail of LMA insertion is defined as body or limb movement, coughing or gagging with 2 minutes after LMA insertion, no proper jaw relaxation(difficult mouth opening), laryngospasm, bronchospasm, desaturation(SpO2\<94%)
Secondary Outcomes
No secondary outcomes reported
Investigators
Sangjin Park
assistant professor
Yeungnam University College of Medicine